A high level of the quality and innovation, the PAREXEL will work with Pfizer to achieve the greater speed and the cost efficiencies in its clinical development programs while delivering a high level of the quality and the innovations to provide the benefits of the Pfizer. The PAREXEL will leverage its proven clinical processes and expertise combined with the market leading eclinical technology platform. Through the partnership with Parexel, the Pfizer will receive the benefits of the industry’s most dynamic and innovative approaches to the strategic partnerships between a services provider and a sponsor. The Pfizer will leverage the PAREXELS, it strengths and scale to execute clinical development programs on a global basis with a greater efficiency and rigor. In June 2011, the partnership model will be implemented over an 18-24 month period beginning.
At Pfizer, the new strategic partnership is part of a comprehensive program to sharpen the research focus. The new strategic partnerhip model is a part of a comprehensive program to sharpen their research focus at Pfizer and it creates more flexible cost base through the outsourcing of the certain research and development services. They are creating partnerships for the activities that can be performed most effectively and efficiently outside of the company and it have selected PARAXEL because it is a leader in providing a combined technology and clinical capabilities.
They chose PAREXEL due to the company’s in depth expertise as well as it is steadfast commitment to the quality and the regulatory compliance, deep belief in the collaboration and the strong drive to deliver success. They look forward to provide innovative solutions and expertise to help the Pfizer accelerate clinical success. The PAREXEL is proud to be selected as a strategic partner and it will work collaboratively with Pfizer to create significant value.
They are focusing on applying best practiceoperational models, supported by a combination of their eclinical solutions and clinical processes, this is to help Pfizer reduce the time and cost of the development. Leveraging their global resources and worldwide technology infrastructure, they can enable more effective information flow and improve data access which results in the greater visibility into the trials and it is ultimately in a better decision making.
REFERENCE:
http://www.pharmpro.com/news/2011/05/outsourcing-news-Pfizer-and-PAREXEL-Sign-Strategic-Partnership-Agreement/
